Topic Listing for Alkermes

Administration Adoption 2006 Stock Option Plan Non-employee Directors
Advertising Promotion Aggregate Fees 2006 2005
Aggregate Fees 2007 2006 Aggregate Fees 2009 2008
Aggregated Option Sar Exercises Last End Values Air Insulin
Air Parathyroid Hormone Air Parathyroid Hormone Pth
Air Pth Alkermes Inc
Alks Amended Restated 1999 Stock Option Plan
Amendment Repricings Amendments
Amylin Anti-takeover Provisions Not Benefit Shareholders
Approval Alkermes Inc 2008 Stock Option Incentive Plan Approval Amended Restated 1999 Stock Option Plan
Approval Amendment 1999 Stock Option Plan Approval Amendment 2002 Restricted Stock Award Plan
Approval Amendment 2006 Stock Option Plan Non-employee Directors Approved Commercial Products Cause Unintended Side Effects Adverse
Asset Retirement Obligations Awards Outstanding Available Future Grant
Base Salary Basis Presentation
Beneficial Ownership Reporting Compliance Biographical Information
Board Committees Board Compensation
Board Directors Committees Borrowings
Business Involves Environmental Risks Business Negatively Affected Result Actions Activist Shareholders
Business Subject Extensive Governmental Regulation Oversight Changes Laws Capital Requirements
Cash Bonus Cash Equivalents
Cash Incentive Bonus Cash Performance Pay
Cephalon Certain Relationships Related Person Transactions
Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act Certifications
Change Control Provisions Change Internal Control Over Financial Reporting
Chief Executive Officer Succession Plan Cilag
Cilag Gmbh International Clinical Products
Clinical Trials Product Candidates Expensive Outcome Uncertain Code Ethics
Collaborative Arrangements Commercial Products
Common Stock Price Highly Volatile Comparison Cumulative Total Returns
Compensation Committee Calendar Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Decisions
Compensation Directors Compensation Mix
Compensation Program Elements Competition
Composition Responsibilities Board Directors Comprehensive Income
Concentrations Consent Independent Registered Public Accounting Firm
Contractual Obligations Cost Goods Manufactured Sold
Critical Accounting Policies Current Compensation Guidelines
Current Credit Financial Market Conditions Exacerbate Certain Risks Customer Base Purchase Vivitrol Directly Highly Concentrated
Deadline Shareholder Proposals Deferred Revenue
Delivery Technologies Product Development Efforts Not Produce Safe Depend Parties Conduct Clinical Trials Product Candidates Failure
Director Qualifications Documents Incorporated Reference
Drug Delivery Technology Earnings Per Share
Effective Date 1999 Plan Effective Date 1999 Stock Option Plan
Effective Date 2002 Plan Effective Date 2006 Plan
Effective Date 2008 Plan Election Directors
Eligible Participants Employee Benefit Plans
Employees Employment Contracts Termination Change-in-control Agreements
Equity Compensation Plan Information Equity Incentives Performance Based Restricted Stock Awards Options
Equity Incentives Stock Options Restricted Awards Unit Estimates
Evaluation Disclosure Controls Procedures Exact Name Registrant Specified Charter
Executive Compensation Philosophy Objectives Executive Compensation Policies
Executive Officer Compensation Determination Executive Officer Loans
Executive Sessions Independent Directors Executive Summary
Exenatide Lar Exenatide Once Weekly
Expenses Expenses Solicitation
Exposed Product Liability Claims Recalls Extended-release Naltrexone
Face Competition Biotechnology Pharmaceutical Industries Others Factors Considered Determining Compensation
Failure Comply Government Regulations Regarding Products Harm Business Fair Value Financial Instruments
Fda Foreign Regulatory Agencies Not Approve Product Candidates Financial Condition
Financing Activities Foreign Currency Exchange Rate Risk
Foreign Currency Exchange Rates Affect Revenue Form 10-k
Form 10-q Former Name Address Changed Since Last Report
Forward-looking Statements Frequency Length Committee Meetings Agenda
Funds Associated Certain Auction Rate Securities Not Accessible Future Transactions Harm Business Market Price Stock
General Good Manufacturing Processes Cgmp
Government Regulation Guarantees
Held 2006 Held 2007
Held 2008 Held 2009
Householding Http Investoralkermescom
Http Wwwcomputersharecom Expressvote Http Wwwenvisionreportscom Alks
Impairment Long-lived Assets Impairment Restructuring Expenses
Incentive Options Income Taxes
Incur Financial Operational Risk Connection Move Headquarters Cambridge Independence Members Board Directors
Independent Registered Auditor Independent Registered Public Accounting Firm
Indevus Index
Injectable Extended-release Drug Delivery Injectable Extended-release Technology
Introduction Introduction Corporate Governance
Inventory Inventory Net
Investing Activities Investment Portfolio Become Impaired Further Deterioration Capital Markets
Investments Issue Additional Common Stock Shareholders Suffer Dilution Investment
Janssen Lease Commitments
Legislative Regulatory Changes Harm Business License Collaboration Agreement Supply Cephalon
License Royalty Commitments Lilly
Limitation Deductions Liquidity Capital Resources
Litigation Litigation Arbitration Result Financial Losses Harm Reputation Divert
Litigation Result Financial Losses Harm Reputation Divert Management Manufacture Products Subject Government Regulation
Manufacturing Manufacturing Product Supply
Manufacturing Revenues Manufacturing Revenues Related Agreements Cephalon
Manufacturing Revenues Related Cephalon Agreements Manufacturing Royalty Revenues
Marketing Marketing Sales
Multiple Element Arrangements Net Collaborative Profit
Net Collaborative Profit Related Agreements Cephalon Net Collaborative Profit Related Cephalon Agreements
New Accounting Pronouncements New Plan Benefits
Non-qualified Options Non-recourse Risperdal Consta Secured Notes
Nonqualified Deferred Compensation 2007 Nonqualified Deferred Compensation 2008
Nonqualified Deferred Compensation 2009 Not Able Develop New Products Business Suffer
Not Able Retain Key Personnel Not Become Profitable Sustained Basis
Not Realize Expected Benefits Restructuring Plan Announced 2008 Not Recoup 100 Investment Reliant
Not Successful Development Products Own Account Number Shares Subject 1999 Plan
Number Shares Subject 2002 Plan Number Shares Subject 2006 Plan
Obligation Capital Lease Off-balance Sheet Arrangements
Once-weekly Exenatide Operating Activities
Operation Board Directors Option Exercises Stock Vested 2007
Option Exercises Stock Vested 2008 Option Exercises Stock Vested 2009
Options Available Future Grant Options Outstanding Exercisable Available Future Grant
Other Assets Other Benefits
Other Business Other Expense Income
Other Income Expense Other Regulations
Ownership Common Stock Ownership Directors Executive Officers
Ownership Principal Stockholders Parachute Payments
Part Part Financial Information
Part Other Information Patent Protection Products Important Uncertain
Patents Proprietary Rights Pension Benefits 2007
Pension Benefits 2008 Pension Benefits 2009
Performance Graph Performance-based Restricted Stock Units
Perquisites Plan
Plan Benefits Policies Governing Director Nominations
Policies Governing Security Holder Communications Board Directors Policy Governing Director Attendance Annual Meetings Shareholders
Post Termination Compensation Benefits Potential Payments Termination Change Control
Potential Tax Liabilities Adversely Affect Results Power Attorney
Principal Features 1999 Plan Principal Features 2002 Plan
Principal Features 2006 Plan Principal Features Amended Restated 1999 Stock Option Plan
Principles Consolidation Procedure Recommendation Director Nominees Shareholders
Process Identifying Evaluating Director Nominees Product Developments
Product Sales Net Product Summary
Products Development Programs Property Plant Equipment
Proposal Provision Income Taxes
Pulmonary Drug Delivery Pulmonary Technology
Ratification Appointment Independent Registered Public Accountants Recent Accounting Pronouncements
Reclassifications Recommendation
Registrants Telephone Number Including Area Code 617 494-0171 Regulation Outside
Reliant Rely Heavily Collaborative Partners
Rely Large Extent Parties Manufacturing Products Rensselaer Polytechnic Institute
Report Audit Committee Report Compensation Committee Executive
Report Independent Registered Public Accounting Firm Require Additional Funds Complete Programs Such Funding Not
Research Development Expense Research Development Expenses
Research Development Revenue Collaborative Arrangements Restricted Stock Award Plan
Restricted Stock Awards Restricted Stock Units
Restructuring Charges Retirement Benefits
Revenue Recognition Revenue Recognition Related License Collaboration Agreement Supply Together
Revenue Related License Collaboration Agreement Supply Together Agreements Revenues Depend Payment Reimbursement Party Payors Reduction Rate
Revenues Depend Payment Reimbursement Third-party Payors Reduction Rate Revoke Proxy
Risks Manufacturing Distribution Products Product Candidates Risperdal Consta
Risperdal Consta Revenues Not Sufficient Repay Royalty Sub Risperdal Consta Vivitrol Product Candidates Not Generate Significant
Royalty Revenues Sales Marketing Experience Limited Capabilities Make Commercializing Products
Sales Marketing Regulations Scheduling Selection Agenda Board Meetings
Segment Information Selling General Administrative Expense
Share Repurchase Programs Share-based Compensation
Share-based Compensation Expense Share-based Compensation Plans
Shareholder Rights Plan Shipping Handling Costs
Signatures Size Board
Stock Option Plan Stock Option Plan Non-employee Directors
Stock Options Stock Options Restricted Common Awards
Stock Performance Graph Strategy
Subject Risks Related Manufacture Products Subordinated Notes
Subsidiaries Substantially Dependent Revenues Principal Product
Succession Plan Tax Aspects Code
Tax Aspects Internal Revenue Code Tax Deductibility Compensation
Tax Deductibility Executive Compensation Term Loan Equipment Financing Arrangement
Termination Provisions Termination Scenarios Voluntary Retirement
Title Class Uncertainty Over Intellectual Property Biotechnology Industry Been Source
Undertake Additional Strategic Acquisitions Future Difficulties Integrating Such Unearned Milestone Revenue
United States Securities Exchange Very Little Sales Marketing Experience Limited Capabilities Make
Vivitrol Vivitrol Not Successfully Marketed Sold Alkermes Generate Significant
Vote Vote Required
Vote-by-telephone 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki